Ovizio develops a patented 4D quantitative microscopy technology based on digital holography that provides automated, in-process viable cell counting to improve accuracy, reproducibility and productivity. Its platform is used in life science research, bioprocessing and diagnostics and has been adopted by global pharmaceutical and biotechnology leaders. The company recently launched the iLine F device for in-line monitoring of viable cell density in bioreactors. Ovizio plans to use the new funds to accelerate commercial activities in the bioprocessing market, further develop its technology and expand its product offering. It intends to strengthen its core R&D team with five new hires in the current year and a further ten in 2016. The company is led by CEO and co-founder Philip Mathuis and is based in Brussels.

Total raised

$9M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2015